Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Natera, Inc.

Oncology Best Practice™ Series: Key Questions for the Community on the Detection and Treatment of MRD

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

Minimal residual disease (MRD) has emerged as a valuable tool in hematologic malignancies, helping clinicians to both predict prognosis and individualize therapy. In patients with solid tumors, MRD testing using cell-free nucleic acids released from malignant cells are being studied for similar roles in predicting patient outcomes and helping to select therapy.

In this program, Pashtoon Kasi, MD, MS, reviewed the emergence of MRD as a tool in the management of patients with solid tumors. The results of MRD research across tumor types and the latest testing methods and technologies used to assess MRD were reviewed. The clinical impact of using MRD across the spectrum of colorectal cancer (CRC) was examined using case presentations. In addition, Dr Kasi responded to questions from the audience on the role of MRD in clinical practice when managing patients with CRC.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Natera, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward academic and community-based oncologists, pathologists, hematologists, nurse practitioners (NPs), pharmacists, physician assistants (PAs) and other health care professionals involved in the detection and treatment of MRD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Assess evolving methods to predict relapse among patients with solid tumors
Explain the rationale underlying the application of ctDNA testing technologies to identify molecular residual disease (MRD) among patients with solid tumors
Describe clinical trial findings in which MRD has been used to monitor patients for early relapse or response in solid tumor settings including gastrointestinal malignancies
Determine how recent evidence on the use of MRD can be considered in the context of real- world clinical scenarios in which patients with solid tumors are monitored for risk of recurrence or early relapse

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Chair

Pashtoon Kasi, MD, MS
Director
Colon Cancer Research
Weill Cornell Medicine
Director
Liquid Biopsy Research
Englander Institute of Precision Medicine
New York, NY

Disclosures: Grant/Research Support: AstraZeneca, Boston Scientific, TerSera Therapeutics LLC; Consultant: AstraZeneca, MSO Oncology, Delcath Systems, Inc., Tempus, Bayer, Lilly, Axiom Healthcare, IPBA, Servier, Taiho.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.